Document is current

Article History

Received: 19 October 2022

Accepted: 23 March 2023

First Online: 12 May 2023

Declarations

:

: This study was approved by the regional ethical review board in Stockholm, Sweden (reference number: 2013/862 − 31/5). The informed consent of the participants is not required for pseudo-anonymized register-based research according to Swedish law (2003:640, § 34) See Ludvigsson et al. (2015) for a review of ethical aspects of registry-based research in the Nordic countries. All methods in the present study were carried out in accordance with relevant guidelines and regulations. Ludvigsson, et al., (2015). Ethical aspects of registry-based research in the Nordic countries. <i>Clinical Epidemiology, 7</i>, 491–508.

: Not applicable.

: Dr Du Rietz reported serving as a speaker for Shire Sweden AB outside the submitted work. Dr Werner-Kiechle reported having stock options in Shire International GmbH and employment by and owning stock or having stock options in Janssen pharmaceuticals. LM Andersson are employed by Takeda Pharma AB. Dr Larsson reported serving as a speaker for Medice, Evolan Pharma AB, and Shire/Takeda and has received grants from Shire/Takeda outside the submitted work. No other disclosures were reported. The other authors do not have any competing interests.